41386-38-3

Upstream product

• 120-47-8 Ethyl 4-hydroxybenzoate 
• 106-93-4 ethylene dibromide 
• 25389-23-5 ethyl 4-(2-hydroxyethoxy)benzoate 
• 37142-39-5 4-(2-bromoethoxy)benzonitrile 
• 29936-92-3 ethyl 4-(ethoxycarbonyl)phenoxyacetate 
• 30893-58-4 4-(ethoxycarbonyl)phenoxyacetic acid 

Downstream Products

• 51616-09-2 4-(β-bromoethoxy)benzoic acid 
• 119932-37-5 diethyl 2-<2-<4-(ethoxycarbonyl)phenoxy>ethyl>malonate 
• 52660-66-9 4-(2-amino-ethoxy)-benzoic acid 
• 85938-29-0 1-acetyl-3-[2-(4-ethoxycarbonylphenoxy)ethyl]-imidazolium iodide 
• 50714-69-7 4-(2-Amino-ethoxy)-benzamide 
• 1440956-48-8 (2-(4-(ethoxycarbonyl)phenoxy)ethyl)boronic acid 
• 1440956-17-1 ethyl 4-(3,3,3-trifluoropropoxy)benzoate 
• 1440956-03-5 C₁₇H₂₅BO₅ 
• 133311-45-2 ethyl 4-[2-(1-piperazinyl)ethoxy]benzoate 
• 1352874-97-5 ethyl 4-(2-(4-(2-oxo-2-(thiazol-2-ylamino)ethyl)piperazin-1-yl)ethoxy)benzoate 
• 869299-53-6 methyl 1-[2-({4-[(methyloxy)carbonyl]phenyl}oxy)ethyl]-4-nitro-1H-pyrazole-5-carboxylate 
• 869299-54-7 methyl 1-[2-({4-[(methyloxy)carbonyl]phenyl}oxy)ethyl]-4-nitro-1H-pyrazole-3-carboxylate 
• 76529-46-9 Ethyl 4-(2-Thioethoxy)benzoate 
• 851133-89-6 4-{2-[2-(3,4-dimethoxy-phenyl)-5,7-dimethoxy-4-oxo-4H-chromen-3-yloxy]-ethoxy}-benzoic acid ethyl ester 

Relevant academic research and scientific papers

New chiral monomers for polymer stabilized cholesteric textures

New mesomorphic chiral acrylates were synthesized. Their additions to a nematic liquid crystalline mixture cause the director of the nematogens molecules to adopt a helically twisted orientation. The pitch of the resulting helicoidal structure is determin

Design, synthesis, biological evaluation and molecular dynamics simulation studies of (R)-5-methylthiazolidin-4-One derivatives as megakaryocyte protein tyrosine phosphatase 2 (PTP-MEG2) inhibitors for the treatment of type 2 diabetes

PTP-MEG2 plays a significant role in insulin production and is able to enhance insulin signaling and improve insulin sensitivity. So, PTP-MEG2 inhibitors are closely associated with type 2 diabetes therapy. A series of novel (R)-5-methylthiazolidin-4-one

Synthesis of some novel pendant-armed cyclen derivatives

A new easy-to-run route to some novel pendant-armed benzene-containing cyclen derivatives is proposed. In this route, the use of potassium carbonate instead of (N,N)-diisopropylethylamine as proton trapper caused a remarkable increase of yields.

Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I)

Kv1.5 potassium channel is an efficacious and safe therapeutic target for the treatment of atrial fibrillation (AF), the most common arrhythmia that threatens human. Herein, by modifying the hit compound 7k from an in-house database, 48 derivatives were synthesized for the assay of their Kv1.5 inhibitory effects by whole cell patch clamp technique. Six compounds which showed better potency than the positive compound dronedarone were selected for the next evaluation of their drug-like properties. Compound 8 exhibited balanced solubility and permeability. It also showed acceptable pharmacodynamics profile with very low acute toxicity. Taking all these data into account, compound 8 can serve as a promising lead for the development of novel therapeutic agent for the treatment of AF.

HETEROCYCLIC COMPOUNDS THAT BLOCK THE EFFECTS OF ADVANCED GLYCATION END PRODUCTS (AGE)

The present invention relates to novel compounds of Formula (Ia) or (Ib), their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. Formula (Ia), or Formula (Ib) in the above formulae L represents Formula (I), Formula (II) or -(CH2)1- Q represents Formula (III), or Formula (IV). The present invention also relates to a process for the preparation of the above said novel compounds, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory responses in tissues, including endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. The present invention also relates to compounds that act as modulators of Perlecan activity and expression. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating heparan sulfate proteoglycans (HSPG) such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as stenosis, restenosis, neointimal hyperplasia, and atherosclerosis. The compounds of Formula (I) are also useful for the treatment and/or prevention of cancer. The types of cancers include melanoma, prostate, leukemia, lymphoma, non-small lung cancers, cancer of the central nervous system, breast, colon, ovarian or renal cancer.

1-[(Aryloxy)alkyl]-1H-imidazoles as inhibitors of neuronal nitric oxide synthase

A series of 1-[(aryloxy)alkyl]-1 H-imidazoles were synthesized from imidazole and various (aryloxy)alkyl bromides and tested for inhibitory activity against the three isoforms of nitric oxide synthase. 1-[2-(4-Bromophenoxy)ethyl]-1 H-imidazole and 1-[2-[4-(trifluoromethyl)phenoxy]ethyl]-1H-imidazole showed inhibitory activity against the neuronal isoform but were less potent against the endothelial isoform. Thus they could be considered interesting for their selectivity. The remaining compounds had only modest activity.

Condensed pyrimidine derivative

A novel pyrimidine derivative having an excellent antitumor activity, which is represented by the following general formula (I) or a pharmacologically acceptable salt thereof: STR1 wherein R1 represents a hydroxyl or amino group; R2 represents a phenylene, pyridinediyl, thiendiyl, furandiyl or thiazoldiyl group, --CO2 R5 and --CO2 R6 may be the same or different from each other and each represents a carboxyl group or a carboxylic acid ester, the part STR2 A represents an oxygen atom, a group represented by the formula: STR3 (wherein R3 and R4 may be the same or different from each other and each represents a hydrogen or halogen atom or a hydrocarbon group which may be substituted, or alternatively R3 and R4 may be united to form an alkylidene group which may be substituted) or a group represented by the formula: STR4 (wherein R70 represents a hydrogen atom or a hydrocarbon group), and n is an integer of 1 to 3, provided that the compound in which R1 represents oxygen, and hydrogen is attached to nitrogen at 3-position is included in the above shown definition, a process for preparation the same, and an antitumor drug containing the same.

Novel 6-5 fused ring heterocycle antifolates with potent antitumor activity: Bridge modifications and heterocyclic benzoyl isosters of 2,4-diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine antifolate

Structural modifications of an extremely potent inhibitor of dihydrofolate reductase (DHFR) activity and tumor cell growth, N-[4-[3-(2,4-diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidin-5-yl)propyl ]benzoyl]-L-glutamic acid (1), have led to the synthesis of

N-Substituted-2-(1-imidazolyl)indoles

Various 1-carboxylic acid substituted-2-(1-imidazolyl)indoles and functional derivatives thereof are highly specific thromboxane synthetase inhibitors. Synthesis of, pharmaceutical compositions thereof, methods of treatment utilizing such compounds and intermediates for their synthesis are included.

Thromboxane synthetase inhibitory N-substituted-2-(1-imidazolyl)indoles

Various 1-carboxylic acid substituted-2-(1-imidazolyl)indoles and functional derivatives thereof are highly specific thromboxane synthetase inhibitors. Synthesis of, pharmaceutical compositions thereof, and methods of treatment utilizing such compounds are included.